Do skutkw ubocznych mona zaliczy bolesno i zaczerwienienie miejsca po iniekcji, a take zwikszenie apetytu, z nadmiern senno i wzdcia
This product is not intended for human or animal use , including ingestion, injection, inhalation, topical application, or any form of administration
These PCAC recommendations largely reverse the FDA's 2023 decision to put these peptides in the high-risk Category 2 "do not compound" bucket
A Cochrane systematic review of NAC for COPD exacerbations (39 RCTs, n=7,436) found that NAC and other mucolytics significantly reduced the frequency of acute exacerbations (OR 0.75, 95% CI 0.62-0.92) (Poole et al., Cochrane Database Syst Rev, 2019) [43]